VistaGen Therapeutics Faces Class Action Lawsuit
Analysis based on 52 articles · First reported Jan 28, 2026 · Last updated Feb 20, 2026
The class action lawsuit against VistaGen Therapeutics for alleged misleading statements regarding its fasedienol drug trial results is expected to negatively impact VistaGen Therapeutics' stock price and investor confidence. It also highlights the role of law firms like Rosen Law Firm and Schall Law Firm in protecting shareholder rights and ensuring market transparency.
VistaGen Therapeutics is facing a class action lawsuit filed by the Rosen Law Firm and the Schall Law Firm. The lawsuit alleges that VistaGen Therapeutics made false and misleading statements to investors between April 1, 2024, and December 16, 2025, regarding the Phase 3 PALISADE-2 trial of its fasedienol drug candidate. The company allegedly created a false impression of positive results and downplayed the risk of failure in clinical studies. When the truth emerged, investors suffered damages. Both law firms are encouraging affected shareholders to join the lawsuit to recover their losses, with a lead plaintiff deadline of March 16, 2026. The lawsuit claims violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the United States===United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard